MARKET

CPRX

CPRX

Catalyst Pharmaceuticals Inc
NASDAQ
23.40
-0.85
-3.51%
After Hours: 23.25 -0.15 -0.64% 19:53 03/27 EDT
OPEN
24.15
PREV CLOSE
24.25
HIGH
24.29
LOW
23.39
VOLUME
754.84K
TURNOVER
--
52 WEEK HIGH
26.58
52 WEEK LOW
19.05
MARKET CAP
2.86B
P/E (TTM)
13.89
1D
5D
1M
3M
1Y
5Y
1D
Catalyst (CPRX) Down 2.5% Since Last Earnings Report: Can It Rebound?
NASDAQ · 2d ago
SRPT Stock Surges on Promising Early Results From siRNA Programs
NASDAQ · 3d ago
Catalyst Pharmaceuticals Inc. Stock Advances 3.2%, Outperforms Peers
Dow Jones · 4d ago
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
NASDAQ · 4d ago
IBRX Stock Slides on FDA Warning Over Misleading Cancer Drug Claims
NASDAQ · 4d ago
VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study
NASDAQ · 5d ago
Weekly Report: what happened at CPRX last week (0316-0320)?
Weekly Report · 6d ago
FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
NASDAQ · 03/20 12:10
More
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.

Webull offers Catalyst Pharmaceuticals Inc stock information, including NASDAQ: CPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CPRX stock methods without spending real money on the virtual paper trading platform.